Corvus Pharmaceuticals Inc
CRVS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.09B
Close$
$0.05
99.6% downside
Current Fair Value
99.6% downsideOvervalued by 99.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.09 Billion |
|---|---|
| Enterprise Value | $1.07 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.19 |
| Beta | 0.86 |
| Outstanding Shares | 92,368,013 |
Return
| Return on Equity | -24.02% |
|---|---|
| Return on Assets | -22.62% |
| Return on Invested Capital | -24.53% |
Valuation & Multiples
| P/E Ratio | -20.17 |
|---|---|
| PEG | -16.2 |
| Price to Sales | - |
| Price to Book Ratio | 6.46 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -19.29 |
| Enterprise Value to Net Income | -20 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3825▲ 5.00% |
|---|---|
| Total Calls | 1,579,740▲ 21.93% |
| Total Puts | 604,200▲ 40.28% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 76.79%▼ 0.96% |
|---|---|
| Total Invested | $1.06B▲ 3.55% |
| Investors Holding | 188▲ 15.00% |
ESG Score
No data
About Corvus Pharmaceuticals Inc
CEO: Richard Miller